Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed- dose combination capsules

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 10, 1998, Pages 824-830

  Zwolska, Z ^a   Niemirowska Mikulska, H ^a   Augustynowicz Kopec, E ^a   Walkiewicz, R ^b   Stambrowska, H ^a   Safianowska, A ^b   Grubek Jaworska, H ^b  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antituberculosis drugs; Bioavailability; Fixed dose; Volunteers

Indexed keywords

ETHAMBUTOL PLUS ISONIAZID; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; RIFATER; TRIFAZID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS;

ADMINISTRATION, ORAL; ADULT; ANTIBIOTICS, ANTITUBERCULAR; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; REFERENCE VALUES; RIFAMPIN;

EID: 0031710482     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Raviglione M C, Snider D E, Kochi A. Global epidemiology of tuberculosis. JAMA 1995; 273: 220-226.
2. Acocella G. Studies of bioavailability in man. Bull Int Union Tuberc Lung Dis 1989; 64: 40-42.
3. Zwolska-Kwiek Z, Niemirowska-Mikulska H. Biovailability of rifampicin and isomazid from Rifamazid produced by Polfa, Poland. Am Rev Respir Dis 1990; 141: 4/2, A 439.
4. Vivien J N, Thibier R, Lepeuple A. La pharmacocinetique de 1'isoniazide dans la race blanche. Rev Fr Mal Respir 1973; 1: 753-772.
5. Le Lirzin M, Vivien J N, Lepeuple A, Thibier R, Pretet S. Dosage microbiologique rapide de l'isoniazid serique. Rev Tuberc Pneumol 1971; 35: 350-356.
6. Acocella G, Pagani V, Marchetti M, Baroni G C, Nicolis F B. Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy 1971; 16: 356-370.
7. Acocella G, Conti R, Luisetti M, Pozzi E, Grassi C. Pharmacokinetic studies on antituberculosis regiments in humans. Am Rev Respir Dis 1985; 132: 510-515.
8. Tallarida R J, Murray R B. Manual of pharmacologic calculations with computer programs. New York; Springer-Verlag 1987; 29: 93.
9. Tallarida R J, Murray R B. Manual of pharmacologic calculation with computer programs, Spring-Verlag, New York, 1987; 40: 134.
10. Fox W. Drug combinations and the bioavailability of rifampicin. Tubercle 1990; 71: 241-245.
11. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the world Health Organisation. Tubercle Lung Dis 1994; 75: 180-181.
12. Ellard G A, Ellard D R, Allen B W, et al. The bioavailability of isomazid, rifampicin and pyrazmamid in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis 1986; 133: 1076-1080.
13. Macnab M F, Bohmer P D, Seager J R. Evaluation of the 3-drug combination, Rifater versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. S Afr Med J 1994, 84; 6: 325-328.
14. Botha F J, Sirgel F A, Parkin D P, van de Wal B W, Donald P R, Mitchison D A. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J 1996; 86: 155-158.
15. Brandli O, Dreher D, Morger D. Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamid. Schweiz-Med-Wochenschr 1993; 123 (25): 1300-1306.
16. Cowie R L. Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial. Tubercle Lung Dis 1996; 77: 239-243.
17. Combs D L, O'Brien R J, Geiter L J. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity and ac- ceptability. The report of final results. Ann Intern Med 1990; 112:397-406.
18. Acocella G, Nonis A, Perna G, Patane E, Gialdrom-Grassi G, Grassi C. Comparative bioavailability of isomazid, rifampicin, and pyrazmamid administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study. Am Rev Respir Dis 1988; 138: 886-890.
19. Geiter L J, O'Brien R J, Combs D L, Snider D Jr. United States public health service tuberculosis therapy a combination tablet of isoniazid, rifampicin and pyrazinamide. Tubercle 1987; 68 (Suppl 2): 41-46.
20. Dautzenberg B. Traitement de la tuberculose en France. Rev Pneumol Clin 1994; 50: 256-259.
21. Moulding T, Dutt A K, Reichman L B. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122: 951-954.